You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
陽光諾和(688621.SH):目前自研立項1類創新藥項目共12項 諾和晟泰在研“STC007 注射液”已進入臨牀二期
格隆匯 12-23 15:46

格隆匯12月23日丨陽光諾和(688621.SH)披露投資者關係活動記錄表顯示,目前公司自研立項1類創新藥項目共12項,進度較快的是控股公司諾和晟泰在研的“STC007 注射液”已經進入臨牀二期,其主要適應症為治療接受血液透析(HD)的成人慢性腎臟疾病相關的中至重度瘙癢(CKD-aP)及治療術後疼痛,“STC008 注射液”於2024年7月獲得臨牀試驗許可,其主要適應症為治療晚期實體瘤的腫瘤惡液質,此外,公司與藝妙神州及其子公司再妙生物合作的自身免疫性疾病品種,治療系統性紅斑狼瘡適應的CAR-T藥物ZM001注射液,已經於2024年7月底申報臨牀受理,於10月取得了藥物臨牀實驗批准通知書,目前已經開始I期臨牀。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account